Compile Data Set for Download or QSAR
maximum 50k data
Found 561 with Last Name = 'shimizu' and Initial = 's'
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194790(US9206167, 11 | US9206167, 12 | USRE48059, Compoun...)
Affinity DataKi:  0.100nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194790(US9206167, 11 | US9206167, 12 | USRE48059, Compoun...)
Affinity DataKi:  0.100nM ΔG°:  -57.1kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194790(US9206167, 11 | US9206167, 12 | USRE48059, Compoun...)
Affinity DataKi:  0.100nM ΔG°:  -57.1kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194790(US9206167, 11 | US9206167, 12 | USRE48059, Compoun...)
Affinity DataKi:  0.100nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194794(US9206167, 15 | USRE48059, Compound of Example 15)
Affinity DataKi:  0.200nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM448338(USRE48059, Compound of Example 139)
Affinity DataKi:  0.200nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194772(US9206167, 139)
Affinity DataKi:  0.200nM ΔG°:  -55.4kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194780(7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butox...)
Affinity DataKi:  0.200nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194794(US9206167, 15 | USRE48059, Compound of Example 15)
Affinity DataKi:  0.200nM ΔG°:  -55.4kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322082(1-{1-(cyclopentylmethyl)-5-[(2,4-difluorobenzyl)ox...)
Affinity DataKi:  0.200nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194780(7-(4-(4-(1-benzothiophen-4-yl)piperazin-1-yl)butox...)
Affinity DataKi:  0.200nM ΔG°:  -55.4kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM593033(1-[1-(Cyclopentylmethyl)-5-{[(2,5-difluorophenyl) ...)
Affinity DataKi:  0.240nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322074(1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.320nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322074(1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.340nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM448330(USRE48059, Compound of Example 90)
Affinity DataKi:  0.400nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194789(US9206167, 10 | USRE48059, Compound of Example 10)
Affinity DataKi:  0.400nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194764(US9206167, 90)
Affinity DataKi:  0.400nM ΔG°:  -53.6kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194789(US9206167, 10 | USRE48059, Compound of Example 10)
Affinity DataKi:  0.400nM ΔG°:  -53.6kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM593018(US11576897, Example 303)
Affinity DataKi:  0.460nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM592980(US11576897, Example 117)
Affinity DataKi:  0.5nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322074(1-{1-(cyclohexylmethyl)-5-[(2,5-difluorobenzyl)oxy...)
Affinity DataKi:  0.5nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194782(US9206167, 3 | USRE48059, Compound of Example 3)
Affinity DataKi:  0.5nM ΔG°:  -53.1kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194783(US9206167, 4 | USRE48059, Compound of Example 4)
Affinity DataKi:  0.5nM ΔG°:  -53.1kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194786(US9206167, 7 | USRE48059, Compound of Example 7)
Affinity DataKi:  0.5nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194783(US9206167, 4 | USRE48059, Compound of Example 4)
Affinity DataKi:  0.5nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194782(US9206167, 3 | USRE48059, Compound of Example 3)
Affinity DataKi:  0.5nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194786(US9206167, 7 | USRE48059, Compound of Example 7)
Affinity DataKi:  0.5nM ΔG°:  -53.1kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322090(US10183913, Example 242 | US11312688, Example 242 ...)
Affinity DataKi:  0.520nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM592999(US11576897, Example 263)
Affinity DataKi:  0.520nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM592972(US11576897, Example 30)
Affinity DataKi:  0.520nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM593013(US11576897, Example 298)
Affinity DataKi:  0.560nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM593015(US11576897, Example 300)
Affinity DataKi:  0.570nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322097(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3-methylbutyl)-1...)
Affinity DataKi:  0.590nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194787(US9206167, 8 | USRE48059, Compound of Example 8)
Affinity DataKi:  0.600nMAssay Description:5-HT2A: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-Ketanserin (final concentration 1 to 3 nM), 20 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194784(US9206167, 5 | USRE48059, Compound of Example 5)
Affinity DataKi:  0.600nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194787(US9206167, 8 | USRE48059, Compound of Example 8)
Affinity DataKi:  0.600nM ΔG°:  -54.8kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Leysen J E et al. (Leysen J E, Niemegeers C J E, Van Nueten J M and Laduron P M. [3H] Ketanserin (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194784(US9206167, 5 | USRE48059, Compound of Example 5)
Affinity DataKi:  0.600nM ΔG°:  -52.6kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322104(1-{1-(2-cyclopentylethyl)-5-[(2,5-difluorobenzyl)o...)
Affinity DataKi:  0.600nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322083(1-{1-(cyclopentylmethyl)-5-[(2,5-difluorobenzyl)ox...)
Affinity DataKi:  0.610nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM592975(US11576897, Example 34 | US11576897, Example 498)
Affinity DataKi:  0.640nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322096(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3,3-dimethylbuty...)
Affinity DataKi:  0.650nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 2A(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM592971(US11576897, Example 20)
Affinity DataKi:  0.650nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322094(1-{5-[(2,5-difluorobenzyl)oxy]-1-(2,2-dimethylprop...)
Affinity DataKi:  0.660nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM593010(US11576897, Example 293)
Affinity DataKi:  0.670nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSodium-dependent serotonin transporter(Homo sapiens (Human))
Sumitomo Pharma

US Patent
LigandPNGBDBM322096(1-{5-[(2,5-difluorobenzyl)oxy]-1-(3,3-dimethylbuty...)
Affinity DataKi:  0.690nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194808(US10501452, Compound B | US9206167, 30 | USRE48059...)
Affinity DataKi:  0.700nM ΔG°:  -52.3kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194802(US9206167, 23 | USRE48059, Compound of Example 23)
Affinity DataKi:  0.700nM ΔG°:  -52.3kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194795(US9206167, 16 | USRE48059, Compound of Example 16)
Affinity DataKi:  0.700nM ΔG°:  -52.3kJ/molepH: 7.4 T: 2°CAssay Description:The assay was performed according to the method by Kohler et al. (Kohler C, Hall H, Ogren S O and Gawell L, Specific in vitro and in vivo binding of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194795(US9206167, 16 | USRE48059, Compound of Example 16)
Affinity DataKi:  0.700nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetD(2) dopamine receptor(Rattus norvegicus (rat))
Otsuka Pharmaceutical

US Patent
LigandPNGBDBM194808(US10501452, Compound B | US9206167, 30 | USRE48059...)
Affinity DataKi:  0.700nMAssay Description:Dopamine D2: The binding assay was performed using 40 μl of the membrane specimen, 20 μl of [3H]-raclopride (final concentration 1 to 2 nM)...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 561 total ) | Next | Last >>
Jump to: